Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Results 81 - 91 of 91 : « Previous 1 2 3 4 5

Recs

0
Member Avatar arseetie (< 20) Submitted: 12/7/2006 4:44:07 PM : Outperform Start Price: $38.23 AMLN Score: -26.23

Amylins potential for effective weight loss drugs will propel this stock forward again starting early next year. Look for a doubling within 36 months

Recs

0
Member Avatar mgbinsd (< 20) Submitted: 11/16/2006 1:06:51 PM : Outperform Start Price: $44.37 AMLN Score: -36.52

Company continues to have very good results on not only their FDA approved drugs, but their pipeline drugs as well.

Recs

0
Member Avatar zino2000 (28.73) Submitted: 11/15/2006 11:00:38 PM : Outperform Start Price: $44.59 AMLN Score: -37.13

2 great drugs for diabetics... huge market...great pipeline for obesity... will be > $100 by 2009

Recs

1
Member Avatar vgettinger (< 20) Submitted: 9/24/2006 10:45:44 PM : Outperform Start Price: $44.15 AMLN Score: -43.11

This company makes two medications currently on the market for Diabetes. However, one of their effects is the potential for significant weight loss. I believe that Byetta for Type 2 DM will be used within one year to prevent diabetes in at risk individuals and within two to three years as weight loss medication that is both more effective and safer than other medications.
The second drug, Symlin, is sort of an orphan drug for both Type 1 and 2 diabetes. I believe this drug will be available as a weight loss drug within the year. When this happens, Amln will fly through the roof.

Recs

0
Member Avatar nepedal (25.71) Submitted: 9/21/2006 5:29:06 PM : Outperform Start Price: $45.66 AMLN Score: -44.70

Byetta is the real deal in diabetes treatment. Everything else in this company (and there's some) is gravy to an investor. As all paradigmatic shifts, Byetta will take time but I think it'll be worth the wait.

Recs

0
Member Avatar Gr8Vette (80.66) Submitted: 9/15/2006 6:08:27 PM : Underperform Start Price: $44.75 AMLN Score: +43.22

One horse show with Byetta. Has had its run up from $16/share to $47/share.

Recs

0
Member Avatar jack0071 (81.31) Submitted: 9/15/2006 7:23:37 AM : Outperform Start Price: $45.87 AMLN Score: -44.92

"Miracle" drugs for diabetics. Sales increasing for the forseeable future. Deep pipeline. Super management.

Recs

1
Member Avatar donklenzman (90.19) Submitted: 9/14/2006 10:25:18 AM : Outperform Start Price: $46.08 AMLN Score: -46.04

20+million diabetics

Recs

0
Member Avatar MudgieBoy (43.67) Submitted: 8/26/2006 2:29:38 AM : Underperform Start Price: $45.15 AMLN Score: +46.68

Burning cash like it is weeds.

Recs

3
Member Avatar carwasher1 (68.80) Submitted: 8/24/2006 3:46:22 AM : Outperform Start Price: $44.74 AMLN Score: -45.76

This company has no where to go but up, albiet slowly. It has a diabetes drug that also helps loose weight. With diabetes and obesity on the rise world wide and Doctors just gaining info on their new drug, it would seem a true winner for all.

Recs

2
Member Avatar stratton6 (98.84) Submitted: 8/6/2006 5:03:57 PM : Outperform Start Price: $47.41 AMLN Score: -51.14

Demand for exenatide is exdeeding capacity (Partnered with Lilly). Collaboration with Alkermes for extended delivery of this product.

Results 81 - 91 of 91 : « Previous 1 2 3 4 5

Featured Broker Partners


Advertisement